We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
What's new
This page lists items that we have published for the first time or updated in the last 7, 30 or 60 days. Use the filters to narrow results by audience, product type, content type or topic.
You can also stay informed by:
- subscribing to our updates to receive same-day notification emails on safety information, scheduling updates or media releases.
- checking for open consultations.
- joining any upcoming events.
This page is in Beta testing. We welcome your feedback and suggestions as we look to improve this page.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (6)
- Breast implant hub (2)
- Clinical trials (1)
- Committees and advisory bodies (6)
- Compliance and enforcement (7)
- Cosmetics (1)
- COVID-19 (1)
- Import and export (2)
- Labelling and packaging (2)
- Legislation (2)
- Manufacturing (3)
- Metal-on-metal hip replacement implants hub (1)
- Safety monitoring and information (21)
- Scheduling (national classification system) (5)
- Shortages and supply disruptions (11)
- Sunscreens (8)
- Unique Device Identification (UDI) hub (7)
- Urogynaecological (transvaginal) surgical mesh hub (1)
- Vaping hub (1)
- Weight loss products (1)
What's new
104 result(s) found, displaying 101 to 104
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
News articlesThis joint statement from the Head of the TGA and Australia’s Chief Medical Officer (CMO), provides you with clear, evidence-informed advice about vaccine safety.
-
Safety updatesThe Product Information for denosumab products indicated for the treatment of osteoporosis have been updated to strengthen the existing warning for multiple vertebral fractures following discontinuation or delay of treatment.
-
Safety alertsThe safety information for denosumab products used to treat osteoporosis has been updated to strengthen the existing warning for multiple spinal fractures after discontinuation or delay of treatment.